Published in Circulation on May 27, 2003
Studies of Left Ventricular Dysfunction (SOLVD) | NCT00000516
Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm (2010) 2.42
Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol (2008) 1.90
Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm (2006) 1.86
Status of the epidemiology of atrial fibrillation. Med Clin North Am (2008) 1.80
Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol (2004) 1.64
Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol (2008) 1.61
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Crit Care Med (2012) 1.58
Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin (2009) 1.38
N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort. Neth Heart J (2008) 1.26
Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins. Antioxid Redox Signal (2013) 1.07
Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol (2005) 1.05
The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm (2008) 1.03
The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. Br J Clin Pharmacol (2008) 1.01
Redox regulation, NF-kappaB, and atrial fibrillation. Antioxid Redox Signal (2009) 1.01
Impaired kidney function and atrial fibrillation in elderly subjects. J Card Fail (2009) 0.92
Age-related atrial fibrosis. Age (Dordr) (2008) 0.90
The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol (2012) 0.90
Regenerative therapies in electrophysiology and pacing. J Interv Card Electrophysiol (2008) 0.89
Atrial endothelial impairment through Toll-like receptor 4 signaling causes atrial thrombogenesis. Heart Vessels (2013) 0.88
Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nat Rev Cardiol (2015) 0.87
Atrial fibrillation: challenges and opportunities. Can J Cardiol (2006) 0.87
Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy? Am J Cardiovasc Dis (2011) 0.87
Epidemiology of stroke in chronic heart failure patients with normal sinus rhythm: findings from the DIG stroke sub-study. Int J Cardiol (2009) 0.84
Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels. Methodist Debakey Cardiovasc J (2016) 0.83
Clinical characteristics of patients with atrial fibrillation at a tertiary care hospital in the central region of Saudi Arabia. J Family Community Med (2011) 0.82
Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis. Kidney Int (2015) 0.82
Oxidative stress, fibrosis, and early afterdepolarization-mediated cardiac arrhythmias. Front Physiol (2013) 0.82
Left atrial pathological degeneration assessed by integrated backscatter transesophageal echocardiography as a predictor of progression to persistent atrial fibrillation: results from a prospective study of three-years follow-up. Cardiovasc Ultrasound (2012) 0.82
Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010. Clin Res Cardiol (2010) 0.81
Atrial fibrillation and inflammation. World J Cardiol (2010) 0.81
Heart failure, diastolic dysfunction and atrial fibrillation; mechanistic insight of a complex inter-relationship. Heart Fail Rev (2012) 0.81
Pharmacological management of atrial fibrillation: one, none, one hundred thousand. Cardiol Res Pract (2011) 0.80
Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol (2011) 0.80
2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations. Clin Hypertens (2015) 0.79
Atrial fibrillation: Blockade of the renin-angiotensin system in atrial fibrillation. Nat Rev Cardiol (2010) 0.78
Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation. Exp Clin Cardiol (2009) 0.78
Measurement of Left Atrial Pressure is a Good Predictor of Freedom From Atrial Fibrillation. Indian Pacing Electrophysiol J (2014) 0.78
[Molecular biology of the heart atrium. New insights into the pathophysiology of atrial fibrillation as well as its clinical implications]. Z Kardiol (2004) 0.78
Non-antiarrhythmic medications for atrial fibrillation: from bench to clinical practice. J Interv Card Electrophysiol (2008) 0.77
Impact of chronic lisinopril therapy on left atrial volume versus dimension in chronic organic mitral regurgitation. Can J Cardiol (2006) 0.77
Beneficial effects of losartan for prevention of paroxysmal atrial fibrillation in patients with sick sinus syndrome: analysis with memory function of pacemaker. Heart Vessels (2015) 0.76
Antiarrhythmic Drugs. Curr Treat Options Cardiovasc Med (2004) 0.76
Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation. Vasc Health Risk Manag (2009) 0.76
Advances in mechanisms of atrial fibrillation: structural remodeling, high-frequency fractionated electrograms, and reentrant AF drivers. J Interv Card Electrophysiol (2008) 0.76
Inflammatory markers in paroxysmal atrial fibrillation and the protective role of renin-angiotensin-aldosterone system inhibitors. Clujul Med (2013) 0.75
Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation. Am Heart J (2016) 0.75
The role of the renin-angiotensin system blocking in the management of atrial fibrillation. J Drug Assess (2012) 0.75
Acetylcholine-regulated K+ current remodelling in the atrium after myocardial infarction and valsartan administration. Can J Cardiol (2009) 0.75
Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection. Vasc Health Risk Manag (2010) 0.75
Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy? CMAJ (2004) 0.75
The Role Of Renin Angiotensin System In Atrial Fibrillation. J Atr Fibrillation (2014) 0.75
Atrial fibrillation. CMAJ (2004) 0.75
Effect of ramipril/hydrochlorothiazide and ramipril/canrenone combination on atrial fibrillation recurrence in hypertensive type 2 diabetic patients with and without cardiac autonomic neuropathy. Arch Med Sci (2016) 0.75
Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF). Can J Cardiol (2008) 0.75
Novel Pharmacological Interventions to Maintain Sinus Rhythm after DC Cardioversion. ISRN Cardiol (2011) 0.75
Prognosis of atrial fibrillation in congestive heart failure. Circulation (2004) 0.75
Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men. Exp Biol Med (Maywood) (2017) 0.75
The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study. Heart Vessels (2016) 0.75
[Upstream therapy for atrial fibrillation]. Herzschrittmacherther Elektrophysiol (2014) 0.75
The Dx-AF study: a prospective, multicenter, randomized controlled trial comparing VDD-ICD to VVI-ICD in detecting sub-clinical atrial fibrillation in defibrillator patients. J Interv Card Electrophysiol (2017) 0.75
Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Are Associated With Improved Outcome but Do Not Prevent New-Onset Atrial Fibrillation After Acute Myocardial Infarction. J Am Heart Assoc (2017) 0.75
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 9.27
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol (2013) 5.67
Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med (2014) 5.41
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14
Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J (2005) 4.06
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation (2010) 3.72
Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation (2002) 3.47
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 3.40
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol (2006) 3.20
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation (2011) 3.01
Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial. Circulation (2013) 2.90
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J (2005) 2.78
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation (2010) 2.51
F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol (2007) 2.50
Symptomatic myocardial bridges: overview of ischemic mechanisms and current diagnostic and treatment strategies. J Am Coll Cardiol (2003) 2.48
Atrial fibrillation promotion by endurance exercise: demonstration and mechanistic exploration in an animal model. J Am Coll Cardiol (2013) 2.38
Left ventricular versus simultaneous biventricular pacing in patients with heart failure and a QRS complex ≥120 milliseconds. Circulation (2011) 2.36
Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation (2008) 2.34
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J (2012) 2.30
Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol (2008) 2.29
Surgical aspects of endovascular retrograde implantation of the aortic CoreValve bioprosthesis in high-risk older patients with severe symptomatic aortic stenosis. J Thorac Cardiovasc Surg (2007) 2.24
Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study. Circulation (2006) 2.23
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J (2009) 2.21
Long-term safety of intravascular ultrasound in nontransplant, nonintervened, atherosclerotic coronary arteries. J Am Coll Cardiol (2005) 2.14
Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol (2007) 2.05
Transmural action potential and ionic current remodeling in ventricles of failing canine hearts. Am J Physiol Heart Circ Physiol (2002) 2.00
Efficacy and safety of cryoballoon ablation for atrial fibrillation: a systematic review of published studies. Heart Rhythm (2011) 1.93
Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation (2007) 1.88
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J (2014) 1.88
Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol (2009) 1.87
Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation (2012) 1.81
Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. Genes Dev (2006) 1.80
The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol (2011) 1.78
Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation (2010) 1.73
Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation (2010) 1.72
Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet (2013) 1.72
Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol (2004) 1.72
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol (2007) 1.70
Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation (2003) 1.69
Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation (2004) 1.64
Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging (2009) 1.63
Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol (2004) 1.62
Absence of association between infectious agents and endothelial function in healthy young men. Circulation (2003) 1.60
Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea. Heart Rhythm (2012) 1.59
Pulmonary vein isolation using a second-generation cryoballoon catheter: a randomized comparison of ablation duration and method of deflation. J Cardiovasc Electrophysiol (2013) 1.57
Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. Eur J Heart Fail (2010) 1.55
Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol (2010) 1.55
Percutaneous mitral valve annuloplasty for ischemic mitral regurgitation: first in man experience with a temporary implant. Catheter Cardiovasc Interv (2007) 1.53
Differences in atrial fibrillation properties under vagal nerve stimulation versus atrial tachycardia remodeling. Heart Rhythm (2009) 1.53
Efficacy and safety of atrial fibrillation ablation with phased radiofrequency energy and multielectrode catheters. Heart Rhythm (2011) 1.51
Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. Cardiovasc Res (2008) 1.51
Atrial fibrillation-associated remodeling does not promote atrial thrombus formation in canine models. Circ Arrhythm Electrophysiol (2012) 1.50
Effects of anesthetic induction in patients with diastolic dysfunction. Can J Anaesth (2009) 1.50
Late iatrogenic coronary stenosis after selective intraoperative antegrade myocardial protection for stentless aortic valve replacement. J Thorac Cardiovasc Surg (2006) 1.48
Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. Circ Heart Fail (2012) 1.48
Shocking truths about implantable cardioverter defibrillator monitoring zones. Pacing Clin Electrophysiol (2007) 1.48
Novel therapeutic aspects of percutaneous aortic valve replacement with the 21F CoreValve Revalving System. Catheter Cardiovasc Interv (2007) 1.45
Histopathology of cryoballoon ablation-induced phrenic nerve injury. J Cardiovasc Electrophysiol (2013) 1.45
Differential effectiveness of pharmacological strategies to reveal dormant pulmonary vein conduction: a clinical-experimental correlation. Heart Rhythm (2011) 1.45
The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol (2012) 1.44
Role of T-type calcium channel subunits in post-myocardial infarction remodelling probed with genetically engineered mice. Cardiovasc Res (2011) 1.44
Incidence and significance of early recurrences associated with different ablation strategies for AF: a STAR-AF substudy. J Cardiovasc Electrophysiol (2012) 1.44
Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J (2003) 1.44
Acute heart failure: perspectives from a randomized trial and a simultaneous registry. Circ Heart Fail (2012) 1.42
Two-year angiographic follow-up of intracoronary Sr90 therapy for restenosis prevention after balloon angioplasty. Circulation (2002) 1.42
Anodal right ventricular capture during left ventricular stimulation in CRT-implantable cardioverter defibrillators. Pacing Clin Electrophysiol (2005) 1.42
Challenge of informing patient decision making: what can we tell patients considering long-term mechanical circulatory support about outcomes, daily life, and end-of-life issues? Circ Cardiovasc Qual Outcomes (2014) 1.41